Learning from Sotorasib: From Mutant-Selective Covalent Inhibitors to Reversible Pan-KRAS Inhibitors
Time: 8:30 am
day: Day One
Details:
• How structural insights from KRAS G12C inhibitors guided the design of inhibitors of other oncogenic KRAS mutants
• Pharmacological profiling of pan-KRAS inhibitors and demonstrations of pre-clinical efficacy
• Insights on the tolerability of wild-type KRAS inhibition and the role of on- and off-state targeting
